Vitamin B12 levels annually or if neurological symptoms develop
Some state Medicaid programs may cover tirzepatide for eligible individuals with type 2 diabetes or weight loss, while others might not include it on their formulary

Monitoring While on Treatment: While using semaglutide through Brightmeds or any platform: Monitor your weight regularly (required monthly for Brightmeds guarantee program) Watch for signs of serious side effects (severe abdominal pain, vision changes, neck swelling, signs of allergic reaction) Stay well-hydrated, especially if experiencing vomiting or diarrhea Contact your provider if side effects become intolerable Do not adjust your dose without provider guidance If you take diabetes medications, monitor blood sugar as directed Report any new or worsening health concerns promptly When to Seek Immediate Medical Attention: Stop using semaglutide and seek emergency medical care if you experience: Severe abdominal pain that doesn't go away (potential pancreatitis) Signs of serious allergic reaction (swelling of face/lips/tongue/throat, difficulty breathing, severe rash) Symptoms of very low blood sugar that don't improve with sugar intake Severe, persistent vomiting or diarrhea leading to dehydration Vision changes or eye pain Signs of gallbladder problems (severe upper abdominal pain, yellowing of skin/eyes, fever) Signs of kidney problems (significantly decreased urination, severe swelling) Drug Interactions to Discuss: Oral Contraceptives: Semaglutide can potentially affect the absorption of oral birth control pills due to delayed gastric emptying

Fen-Phen, a combination of fenfluramine and phentermine, was once heralded as a revolutionary weight loss drug in the 1990s
Recognising Allergic Reactions to GLP-1 Agonists Common Symptoms and Warning Signs to Watch For What to Do If You Experience an Allergic Reaction Risk Factors and Who May Be More Susceptible Alternative Treatments and Next Steps Scientific References Frequently Asked Questions What Are GLP-1 Agonists and How Do They Work
Lancet Diabetes Endocrinol 2015;3:866-75.ArticlePubMedPMC 77